Literature DB >> 2525447

Single-dose and steady-state pharmacokinetics of doxazosin given in combination with chlorothiazide to hypertensive subjects.

E L Conway1, J J McNeil, L Meng, O H Drummer, L G Howes, K Raymond, W J Louis.   

Abstract

The pharmacokinetics of doxazosin were determined in hypertensive subjects after a single dose of 1 mg, and at steady-state while receiving doses of 1, 2, 4 and 8 mg of the drug daily. Chlorothiazide 500 mg once daily was administered as additional therapy throughout the study. After a single dose doxazosin was rapidly absorbed, with peak plasma drug concentrations (Cmax) occurring after 2.1 +/- 0.4 hours. The elimination half-life in plasma was 10.7 +/- 1.2 hours. These parameters remained essentially unchanged during maintenance administration of doxazosin at each of the dose levels. Calculations of Cmax and area under the concentration-time curve (AUC0----infinity) indicated that the pharmacokinetic disposition of the drug remained linear over the dose range 1 to 8 mg.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525447     DOI: 10.2165/00003088-198916060-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  9 in total

1.  Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin.

Authors:  J J McNeil; O H Drummer; E L Conway; B S Workman; W J Louis
Journal:  J Cardiovasc Pharmacol       Date:  1987-08       Impact factor: 3.105

Review 2.  Adrenergic effects on plasma lipoprotein metabolism. Speculation on mechanisms of action.

Authors:  F M Sacks; V J Dzau
Journal:  Am J Med       Date:  1986-02-14       Impact factor: 4.965

3.  The pharmacokinetics of doxazosin in elderly normotensives.

Authors:  J Vincent; P A Meredith; H L Elliott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

4.  Hemodynamic changes at rest and during exercise in long-term prazosin therapy for essential hypertension.

Authors:  P Lund-Johansen
Journal:  Postgrad Med       Date:  1975-11       Impact factor: 3.840

5.  Prazosin disposition in young and elderly subjects.

Authors:  P C Rubin; P J Scott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

6.  Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man.

Authors:  J Vincent; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

7.  A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension.

Authors:  M H Frick; P Halttunen; P Himanen; M Huttunen; P Pörsti; T Pitkäjärvi; L Pöyhönen; M L Pyykönen; P Reinikainen; P Salmela
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

8.  Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise.

Authors:  P Lund-Johansen; P Omvik; H Haugland
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

9.  The antihypertensive effects of doxazosin: a clinical overview.

Authors:  D A Cox; J P Leader; J A Milson; W Singleton
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

  9 in total
  1 in total

Review 1.  Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.

Authors:  B Fulton; A J Wagstaff; E M Sorkin
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.